Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonyf NVXPAR:MLBON 12 PS Ratio is 5.20 as of Aug. 02, 2026, which is 80% below its 10-year median of 25.53. GuruFocus rates XPAR:MLBON with a GF Score™ of 12/100 and a GF Value™ of €8.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Bonyf NV ranks worse than 70.52% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Bonyf NV's share price is €2.48.
Bonyf NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.48. Hence, Bonyf NV's PS Ratio for today is 5.20.
Good Sign:
Bonyf NV stock PS Ratio (=5.2) is close to 3-year low of 5.2.
The historical rank and industry rank for Bonyf NV's PS Ratio or its related term are showing as below:
XPAR:MLBON'
s PS Ratio Range Over the Past 10 Years
Min: 2.98 Med: 25.53 Max: 39.83
Current: 5.2
During the past 5 years, Bonyf NV's highest PS Ratio was 39.83. The lowest was 2.98. And the median was 25.53.
XPAR:MLBON's PS Ratio is ranked worse than 70.52% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.925
vs XPAR:MLBON: 5.20
Bonyf NV revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Bonyf NV was -9.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -50.90% per year.
During the past 5 years, Bonyf NV's highest 3-Year average Revenue per Share Growth Rate was -50.90% per year. The lowest was -54.10% per year. And the median was -52.50% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Bonyf NV PS Ratio Related Terms
Bonyf NV PS Ratio Historical Data
* Premium members only.
The historical data trend for Bonyf NV's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonyf NV PS Ratio Chart
Bonyf NV Annual Data
Trend
Dec19
Dec20
Dec22
Dec23
Dec24
PS Ratio
0.00
0.00
25.53
22.86
37.74
Bonyf NV Semi-Annual Data
Dec19
Dec20
Dec22
Dec23
Dec24
PS Ratio
0.00
0.00
25.53
22.86
37.74
XPAR:MLBON vs ISRG, BDX, MDLN: PS Ratio Comparison
For the Medical Instruments & Supplies subindustry, Bonyf NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonyf NV PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonyf NV's PS Ratio distribution charts can be found below:
* The bar in red indicates where Bonyf NV's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Bonyf NV's Share Price of today is €2.48.
For company reported annually, GuruFocus uses latest annual data as the TTM data. Bonyf NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.48.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Bonyf NV (XPAR:MLBON) has a PS Ratio of 5.20 as of Aug. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bonyf NV and its competitors. This is 80% below median its historical median of 25.53. Over the past decade, Bonyf NV's PS Ratio has ranged from 2.98 to 39.83. According to the industry distribution chart, Bonyf NV ranks #567 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 70.5%.
Is Bonyf NV's PS Ratio too high?
Bonyf NV's current PS Ratio of 5.20 is 80% below median its 10-year median of 25.53. Over the past 10 years, this metric has ranged from a low of 2.98 to a high of 39.83. The Medical Devices & Instruments industry median PS Ratio is 2.93. Bonyf NV's value of 5.20 is 77.8% above this industry median. Based on the distribution chart, Bonyf NV ranks #567 out of 804 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bonyf NV has a GF Score™ of 12/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonyf NV's PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonyf NV ranks #567 out of 804 companies for PS Ratio. This places Bonyf NV in the lower half of its industry. The industry median PS Ratio is 2.93. Bonyf NV's value of 5.20 is 77.8% above this benchmark. Historically, Bonyf NV's own PS Ratio has ranged from 2.98 to 39.83 over the past decade. While the company's 10-year median is 25.53 vs. the industry median of 2.93, Bonyf NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.93, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonyf NV's current PS Ratio of 5.20 is 77.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Bonyf NV and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonyf NV's current PS Ratio is 5.20, which is 80% below median its own 10-year median of 25.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonyf NV stock overvalued right now?
Based on GuruFocus' analysis, Bonyf NV (XPAR:MLBON) is currently considered Possible Value Trap. The stock's GF Value™ is €8.61, compared to a current price of €2.48 — trading 71.2% below its estimated fair value. The current PS Ratio is 5.20, which is 80% below median its 10-year median of 25.53 and 77.8% above the Medical Devices & Instruments industry median of 2.93. Bonyf NV's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Bonyf NV (XPAR:MLBON), the current PS Ratio is 5.20 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonyf NV (XPAR:MLBON) Overvalued in 2026?
Based on GuruFocus' analysis, Bonyf NV stock appears to be undervalued.
The current stock price of €2.48 is trading 71.2% below its estimated GF Value™ of €8.61.
GuruFocus considers Bonyf NV to be Possible Value Trap.
Key valuation signals for XPAR:MLBON:
PS Ratio: 5.20 (80% below median its 10-year median of 25.53)
GF Value™: €8.61 vs. price of €2.48 (71.2% below fair value)
Industry Position: 77.8% above the Medical Devices & Instruments median (#567 of 804)
No single metric tells the full story. See the XPAR:MLBON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonyf NV specializes in developing, producing and selling cutting-edge oral & dental care products. It is a forward-thinking company committed to revolutionizing oral care through innovation and research.
12GF Score
Get the complete analysis for XPAR:MLBON
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLBON has been successfully added to your 
